This website has been developed and fully funded by Janssen-Cilag Ltd. and is intended for UK patients prescribed Tremfya®▼ (guselkumab) only.

Information on COVID-19 for patients using Tremfya® (guselkumab)
Access Covid-19

This guidance is correct as of March 2021.

COVID-19: Information for patients prescribed Tremfya® (Guselkumab)

We understand that if you are currently prescribed TREMFYA® (guselkumab) you may have questions about COVID-19 and your treatment. The medical community is still learning about COVID-19, so specific information about the virus and our medicines is not currently available.

If you have any queries in relation to your TREMFYA® medication, you can contact our Medical Information team on 01494 567447 or via email at medinfo@its.jnj.com.

Considerations regarding your medication

If you have any questions regarding taking or continuing your medicines in relation to COVID-19, please speak to your doctor or nurse in the first instance.

The current advice is that you should not stop taking your medications or make changes to your medication unless advised to do so by your doctor or nurse (e.g. dermatologist or biologics nurse).1

If you think you may have symptoms of COVID-19, get in touch with your doctor or nurse.

Be aware that you should not use this medication if you have an active infection, including active tuberculosis. If you think you have an infection, or have symptoms of an infection, please contact your doctor, pharmacist or nurse.2 For more information, including some of the signs of infection you should be looking out for during your treatment, please refer to the Patient Information Leaflet (PIL).

Vaccinations while taking TREMFYA®

It is recommended that live viral or live bacterial vaccines should not be given alongside TREMFYA®.3

If you would like to discuss this further, please speak with your doctor or nurse.

Other useful information

For patients living with psoriasis or psoriatic arthritis you may wish to visit the COVID-19 information page on the Psoriasis Association UK website for further information on COVID-19 and general guidance regarding coronavirus vaccines which may be useful to you.

NHS and UK Government information:

We recommend you also visit the COVID-19 advice page on the NHS website, and follow the NHS guidelines for limiting risk of infection. Further information on UK Government COVID-19 advice, including self-isolation guidance, is also available on the Gov.uk website.

Reporting side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also call Janssen-Cilag Ltd Drug Safety on 01494 567447 or at dsafety@its.jnj.com.

By reporting side effects you can help provide more information on the safety of this medicine.

References

  1. Psoriasis Association: COVID-19 Information. Available from: https://www.psoriasis-association.org.uk/psoriasis-and-treatments/covid-19-information [Last accessed March 2021].
  2. Tremfya® Patient Information Leaflet. Available from: https://www.medicines.org.uk/emc/files/pil.9587.pdf [Last accessed March 2021].
  3. Janssen-Cilag Ltd. Tremfya® (guselkumab) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc [Last accessed March 2021].